AR039883A1 - Combinacion farmaceutica - Google Patents

Combinacion farmaceutica

Info

Publication number
AR039883A1
AR039883A1 ARP030101592A ARP030101592A AR039883A1 AR 039883 A1 AR039883 A1 AR 039883A1 AR P030101592 A ARP030101592 A AR P030101592A AR P030101592 A ARP030101592 A AR P030101592A AR 039883 A1 AR039883 A1 AR 039883A1
Authority
AR
Argentina
Prior art keywords
pharmaceutical combination
compound
clause
arrhythmia
anticoagulant
Prior art date
Application number
ARP030101592A
Other languages
English (en)
Inventor
Ann-Charlotte Roth-Rosendhal
Elisabeth Svernhage
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR039883A1 publication Critical patent/AR039883A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines having two or more nitrogen atoms in the same ring, e.g. oxadiazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06Tripeptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Un producto de combinación que comprende: (a)un anticoagulante; y (b) (1) un compuesto como el que se define en la cláusula 1 de WO 01/28992 o (2) un compuesto de la cláusula 34 de WO 01/28992 o (3) el compuesto A o B o C o D (o sales del mismo aceptables para uso farmacéutico) para utilizar en el tratamiento de arritmia o una complicación de la misma controlada por la coagulación.
ARP030101592A 2002-05-06 2003-05-06 Combinacion farmaceutica AR039883A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0201374A SE0201374D0 (sv) 2002-05-06 2002-05-06 Pharmaceutical combination

Publications (1)

Publication Number Publication Date
AR039883A1 true AR039883A1 (es) 2005-03-09

Family

ID=20287789

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP030101592A AR039883A1 (es) 2002-05-06 2003-05-06 Combinacion farmaceutica

Country Status (19)

Country Link
US (1) US20050119259A1 (es)
EP (1) EP1503783A1 (es)
JP (1) JP2005529140A (es)
KR (1) KR20040104692A (es)
CN (1) CN1652812A (es)
AR (1) AR039883A1 (es)
AU (1) AU2003230517A1 (es)
BR (1) BR0309336A (es)
CA (1) CA2485086A1 (es)
IL (1) IL164939A0 (es)
IS (1) IS7536A (es)
MX (1) MXPA04010717A (es)
NO (1) NO20044555L (es)
PL (1) PL372526A1 (es)
RU (1) RU2004129729A (es)
SE (1) SE0201374D0 (es)
TW (1) TW200307549A (es)
WO (1) WO2003092720A1 (es)
ZA (1) ZA200408618B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20042068A1 (it) * 2004-10-29 2005-01-29 Opocrin Spa Nuovo uso di eparine a bassissimo peso molecolare
AR053901A1 (es) * 2005-06-20 2007-05-23 Astrazeneca Ab Formas fisicas de oxabispidinas n,n'- disustituidas

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU178398B (en) * 1979-06-12 1982-04-28 Gyogyszerkutato Intezet Process for producing new agmatine derivatives of activity against haemagglutination
SE9903759D0 (sv) * 1999-10-18 1999-10-18 Astra Ab Pharmaceutically active compounds
US6462021B1 (en) * 2000-11-06 2002-10-08 Astrazeneca Ab Use of low molecular weight thrombin inhibitor

Also Published As

Publication number Publication date
ZA200408618B (en) 2006-06-28
US20050119259A1 (en) 2005-06-02
AU2003230517A1 (en) 2003-11-17
BR0309336A (pt) 2005-03-08
WO2003092720A1 (en) 2003-11-13
PL372526A1 (en) 2005-07-25
EP1503783A1 (en) 2005-02-09
IS7536A (is) 2004-11-18
IL164939A0 (en) 2005-12-18
TW200307549A (en) 2003-12-16
NO20044555L (no) 2004-11-16
CN1652812A (zh) 2005-08-10
WO2003092720A8 (en) 2005-03-10
SE0201374D0 (sv) 2002-05-06
MXPA04010717A (es) 2005-03-07
JP2005529140A (ja) 2005-09-29
CA2485086A1 (en) 2003-11-13
KR20040104692A (ko) 2004-12-10
RU2004129729A (ru) 2005-07-10

Similar Documents

Publication Publication Date Title
ES2572454T3 (es) Tratamiento de enfermedades mediadas por los linfocitos T
ECSP066365A (es) Anilino purinas sustituidas en la posición 6 útiles como inhibidores de rtk
AR054060A1 (es) Forma de dosificacion farmaceutica unitaria
AR026610A1 (es) Un derivado pirrolidinacetamida solo o en combinacion para tratamiento de desordenes del sistema nervioso central
CR8278A (es) Combinaciones sinergicas de productos activos, fungicidas
CY1110835T1 (el) Διφαινυλ παραγωγα και η χρηση τους στη θεραπεια της ηπατιτιδας c
GT200600163A (es) Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de la depresion
ECSP045491A (es) Nueva sal formiato de o-desmetil venlafaxina
ECSP045407A (es) Benzazoles sustituidos y el uso del mismo como inhibidores de quinasa raf
AR027355A1 (es) Acidos tiazolidincarboxilicos
UY27186A1 (es) Formulación farmacéutica
EA200500399A1 (ru) Ненуклеозидные ингибиторы обратной транскриптазы
UY27755A1 (es) Nuevas composiciones farmacéuticas basadas en anticolinérgicos e inhibidores.
ATE401875T1 (de) Pharmazeutische feste dispersionen von modafinil- verbindungen
AR024998A1 (es) Nuevos retinoides para el tratamiento del enfisema
UY26371A1 (es) Imidazo-3-il-aminas biciclicas, procedimiento para su preparacion y medicamentos que las contienen
HRP20070291T3 (en) Pharmaceutical composition comprising a zinc-hyaluronate complex for the treatment of multiple sclerosis
BRPI0416005A (pt) tiazolidinonas, na preparação e utilização como medicamento
AR026254A1 (es) El uso de una preparacion de liberacion controlada para la preparacion de un medicamento para aumentar la dosis o la exposicion sistemica de un farmaco queinhibe la fosfodiesterasa 4
CO2024002748A2 (es) Profármaco de derivados de pirrolidona como activador de glucocinasa
ECSP056190A (es) Compuestos utiles en la terapia de la enfermedad de alzheimer y formulaciones que los contienen
PA8651401A1 (es) Formas de dosificacion oral solidas que contienen una dosis baja de estradiol
AR039883A1 (es) Combinacion farmaceutica
DE50111407D1 (de) Mittel enthaltend n-chlortaurin sowie dessen verwendung zur behandlung von schleimhautpolypen
AR024981A1 (es) Composicion para la prevencion y el tratamiento de las disfunciones y enfermedades del rinon

Legal Events

Date Code Title Description
FA Abandonment or withdrawal